Perinatal Dysbiosis, Lung Development and Asthma
围产期生态失调、肺部发育和哮喘
基本信息
- 批准号:10187646
- 负责人:
- 金额:$ 39.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-10 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcetatesAdolescentAdultAllergensAlveolarAnimal ModelAnimalsAntibioticsAsthmaAutomobile DrivingBiological AssayBirthBreast FeedingCellsCellular StructuresCesarean sectionCommunitiesCuesDataDevelopmentDiseaseElderlyEndotheliumEnvironmental ExposureEpithelialEpithelial CellsEquilibriumExposure toExtrinsic asthmaGenetic Predisposition to DiseaseGoalsHealthHomeostasisHumanImmuneImmune responseInterleukin-17InterventionLifeLinkLungMediatingMesenchymalMesenchymeMucosal Immune SystemMucous MembraneMusNatureNeonatalOrganoidsPathogenesisPathogenicityPatternPerinatalPerinatal ExposurePermeabilityPhenocopyPhenotypePlayPredispositionPrevalenceProductionPublic HealthPyroglyphidaeRegulationRiskRisk FactorsRoleSeveritiesSignal PathwaySignal TransductionSiteStructural defectStructureSupplementationSurfaceT-LymphocyteTestingTherapeuticWorkairway hyperresponsivenesschemokinechronic inflammatory diseasecigarette smokecommensal bacteriadesigndysbiosisearly life exposureepidemiologic datahuman diseasein vivoinsightinterleukin-22knockout animallung developmentmicrobialmicrobial colonizationmicrobiomenoveloffspringperinatal periodprophylacticreceptorrecruitresponse
项目摘要
Environmental exposures that alter asthma risk (C-section, breast feeding) also influence microbial colonization.
Dysbiosis regulates mucosal IL-17A and IL-22 levels differently, reducing IL-22 production while enhancing the
recruitment of IL-17A-producing cells. As IL-22 mediates homeostasis at mucosal surfaces, and IL-17A
production is associated more severe asthma phenotypes, this suggests dysbiosis-induced regulation of asthma
pathogenesis may involve an underappreciated dysregulation of the IL-22/IL-17A balance. Our preliminary data
show that: (1) perinatal dysbiosis induces lung structural changes, increased baseline airway hyperreactivity
(AHR), and exaggerated house dust mite (HDM)-induced asthma phenotype (more severe AHR, elevated
chemokine production, enhanced recruitment of IL-17A-producing cells); (2) organoids derived from dysbiosis-
exposed epithelial cells demonstrate reduced colony forming efficiency and increased HDM-stimulated
chemokine production; (3) IL-17A blockade abrogates perinatal dysbiosis-augmented, HDM-induced AHR; (4)
perinatal IL-22 blockade recapitulates some features of perinatal dysbiosis (increased airway responses and
lung permeability in HDM-naïve adolescent mice); (5) IL-22Ra1 expression is regulated developmentally on
pulmonary mesenchymal cells; and (6) supplementation with acetate reverses perinatal dysbiosis-induced
alveolar permeability. Thus, we hypothesize that perinatal dysbiosis-induced reduction in neonatal mesenchymal
IL-22 signaling drives altered lung development, increased allergen-driven recruitment of IL-17A-producing cells
and more severe asthma later in life, and that bacterial metabolite supplementation will reverse these
phenotypes. This hypothesis will be tested in three Aims: Aim 1: To define mechanisms driving increased
allergen-induced IL-17A-producing cell recruitment and identify the IL-17A-secreting cells driving severe
asthma after perinatal dysbiosis, we will determine if perinatal dysbiosis influences immune cell
responsiveness to chemotactic signaling, identify pulmonary structural cells responsible for increased chemokine
production, and identify which IL-17A-producing ILCs are necessary and sufficient to drive the structural and
asthma phenotypes observed after perinatal dysbiosis. Aim 2: To determine if perinatal IL-22 signaling in
mesenchymal cells influences pulmonary development, baseline AHR, and the severity of allergen-
driven AHR, we will target IL-22-activated signaling pathways in mesenchymal cells during critical neonatal
windows in control mice, and supplement animals exposed to perinatal dysbiosis with rIL-22 or IL-22 producing
cells, and assess the impact on dysbiosis-induced phenotypes, Aim 3: To determine if dysbiosis-induced
alterations in lung development or asthma severity can be reversed by supplementation with bacterial
metabolites, we will test the capacity of bacterial metabolites administered prophylactically and therapeutically
to reverse dysbiosis-induced phenotypes. Collectively, these studies will elucidate the mechanisms by which
perinatal dysbiosis influences asthma development.
改变哮喘风险的环境暴露(剖腹产,母乳喂养)也会影响微生物定植。
菌群失调以不同的方式调节粘膜IL-17 A和IL-22水平,减少IL-22的产生,同时增强粘膜细胞的增殖。
IL-17 A产生细胞的募集。由于IL-22介导粘膜表面的稳态,而IL-17 A
生产与更严重的哮喘表型相关,这表明生态失调诱导的哮喘调节
发病机制可能涉及IL-22/IL-17 A平衡的未被充分认识的失调。我们的初步数据
表明:(1)围产期生态失调引起肺结构变化,增加基线气道高反应性
(AHR)和夸大的屋尘螨(HDM)诱导的哮喘表型(更严重的AHR,升高)
趋化因子产生,IL-17 A产生细胞的增强募集);(2)源自生态失调的类器官-
暴露的上皮细胞表现出集落形成效率降低和HDM刺激的集落形成效率增加。
(3)IL-17 A阻断消除围产期生态失调增强的HDM诱导的AHR;(4)
围产期IL-22阻断概括了围产期生态失调的一些特征(增加的气道反应和
(5)IL-22 Ra 1的表达在发育过程中受到调节,
肺间充质细胞;和(6)补充醋酸盐逆转围产期生态失调诱导的
肺泡通透性因此,我们假设围产期生态失调引起的新生儿间充质细胞减少,
IL-22信号传导驱动肺发育改变,增加过敏原驱动的IL-17 A产生细胞的募集
以及在以后的生活中更严重的哮喘,而细菌代谢物补充剂将逆转这些
表型这一假设将在三个目标中得到检验:目标1:
过敏原诱导的IL-17 A产生细胞募集,并确定IL-17 A分泌细胞驱动严重的
围产期生态失调后的哮喘,我们将确定围产期生态失调是否影响免疫细胞
对趋化性信号传导的反应,确定负责增加趋化因子的肺结构细胞
生产,并确定哪些IL-17 A-生产ILC是必要的和足够的驱动结构和
围产期生态失调后观察到的哮喘表型。目的2:确定是否围产期IL-22信号转导在
间充质细胞影响肺发育、基线AHR和过敏原的严重程度-
驱动AHR,我们将在新生儿重症监护期间靶向间充质细胞中的IL-22激活的信号通路。
对照小鼠和暴露于围产期生态失调的补充动物中的rIL-22或IL-22产生
目的3:确定生态失调诱导的表型是否与细胞的生长有关,并评估对生态失调诱导的表型的影响。
肺发育或哮喘严重程度的改变可以通过补充细菌
代谢物,我们将测试细菌代谢物的能力,
来逆转生态失调引起的表型总的来说,这些研究将阐明
围产期生态失调影响哮喘的发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ian Paul Lewkowich其他文献
Ian Paul Lewkowich的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ian Paul Lewkowich', 18)}}的其他基金
Airway inflammation and fear: neuroimmune mechanisms and forebrain circuits
气道炎症和恐惧:神经免疫机制和前脑回路
- 批准号:
10677767 - 财政年份:2022
- 资助金额:
$ 39.85万 - 项目类别:
Airway inflammation and fear: neuroimmune mechanisms and forebrain circuits
气道炎症和恐惧:神经免疫机制和前脑回路
- 批准号:
10668648 - 财政年份:2022
- 资助金额:
$ 39.85万 - 项目类别:
Preconceptual paternal allergen exposure, offspring asthma, and pulmonary gamma/delta T cell function
孕前父亲过敏原暴露、后代哮喘和肺 γ/δ T 细胞功能
- 批准号:
10300217 - 财政年份:2021
- 资助金额:
$ 39.85万 - 项目类别:
Preconceptual paternal allergen exposure, offspring asthma, and pulmonary gamma/delta T cell function
孕前父亲过敏原暴露、后代哮喘和肺 γ/δ T 细胞功能
- 批准号:
10427457 - 财政年份:2021
- 资助金额:
$ 39.85万 - 项目类别:
Perinatal Dysbiosis, Lung Development and Asthma
围产期生态失调、肺部发育和哮喘
- 批准号:
10405015 - 财政年份:2020
- 资助金额:
$ 39.85万 - 项目类别:
Perinatal Dysbiosis, Lung Development and Asthma
围产期生态失调、肺部发育和哮喘
- 批准号:
10625311 - 财政年份:2020
- 资助金额:
$ 39.85万 - 项目类别:
Preconceptual paternal environmental allergen exposure, sperm epigenetics and offspring asthma development
孕前父亲环境过敏原暴露、精子表观遗传学和后代哮喘发展
- 批准号:
9980030 - 财政年份:2020
- 资助金额:
$ 39.85万 - 项目类别:
Impact of prenatal HDM exposure in severely asthmatic mothers on offspring asthma
严重哮喘母亲产前暴露于 HDM 对后代哮喘的影响
- 批准号:
9243430 - 财政年份:2016
- 资助金额:
$ 39.85万 - 项目类别:
Mechanisms of IL-17A-mediated enhancement of asthma severity
IL-17A 介导的哮喘严重程度增强的机制
- 批准号:
8670181 - 财政年份:2014
- 资助金额:
$ 39.85万 - 项目类别:
Mechanisms of IL-17A-mediated enhancement of asthma severity
IL-17A 介导的哮喘严重程度增强的机制
- 批准号:
8842705 - 财政年份:2014
- 资助金额:
$ 39.85万 - 项目类别:
相似海外基金
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 39.85万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The impact of changes in social determinants of health on adolescent and young adult mental health during the COVID-19 pandemic: A longitudinal study of the Asenze cohort in South Africa
COVID-19 大流行期间健康社会决定因素的变化对青少年和年轻人心理健康的影响:南非 Asenze 队列的纵向研究
- 批准号:
10755168 - 财政年份:2023
- 资助金额:
$ 39.85万 - 项目类别:
A Priority Setting Partnership to Establish a Patient, Caregiver, and Clinician-identified Research Agenda for Adolescent and Young Adult Cancer in Canada
建立优先合作伙伴关系,以建立患者、护理人员和临床医生确定的加拿大青少年和年轻人癌症研究议程
- 批准号:
480840 - 财政年份:2023
- 资助金额:
$ 39.85万 - 项目类别:
Miscellaneous Programs
Incidence and Time on Onset of Cardiovascular Risk Factors and Cardiovascular Disease in Adult Survivors of Adolescent and Young Adult Cancer and Association with Exercise
青少年和青年癌症成年幸存者心血管危险因素和心血管疾病的发病率和时间以及与运动的关系
- 批准号:
10678157 - 财政年份:2023
- 资助金额:
$ 39.85万 - 项目类别:
Fertility experiences among ethnically diverse adolescent and young adult cancer survivors: A population-based study
不同种族青少年和年轻成年癌症幸存者的生育经历:一项基于人群的研究
- 批准号:
10744412 - 财政年份:2023
- 资助金额:
$ 39.85万 - 项目类别:
Treatment development for refractory leukemia using childhood/adolescent, and young adult leukemia biobank
利用儿童/青少年和青年白血病生物库开发难治性白血病的治疗方法
- 批准号:
23K07305 - 财政年份:2023
- 资助金额:
$ 39.85万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular design of Two-Way Player CAR-T cells to overcome disease/antigen heterogeneity of childhood, adolescent, and young adult cancers
双向 CAR-T 细胞的分子设计,以克服儿童、青少年和年轻成人癌症的疾病/抗原异质性
- 批准号:
23H02874 - 财政年份:2023
- 资助金额:
$ 39.85万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Effects of adolescent social isolation on adult decision making and corticostriatal circuitry
青少年社会隔离对成人决策和皮质纹状体回路的影响
- 批准号:
10756652 - 财政年份:2023
- 资助金额:
$ 39.85万 - 项目类别:
Adolescent trauma produces enduring disruptions in sleep architecture that lead to increased risk for adult mental illness
青少年创伤会对睡眠结构产生持久的破坏,从而导致成人精神疾病的风险增加
- 批准号:
10730872 - 财政年份:2023
- 资助金额:
$ 39.85万 - 项目类别:
Using Tailored mHealth Strategies to Promote Weight Management among Adolescent and Young Adult Cancer Survivors
使用量身定制的移动健康策略促进青少年和年轻癌症幸存者的体重管理
- 批准号:
10650648 - 财政年份:2023
- 资助金额:
$ 39.85万 - 项目类别: